The evaluation of cytokines and hormones as biomarkers for EHE
Research type
Research Study
Full title
The evaluation of cytokines and hormones as biomarkers for Epithelioid Haemangioendothelioma
IRAS ID
287969
Contact name
Robin Jones
Contact email
Sponsor organisation
Fondazione IRCCS Istituto Nazionale Tumori
Duration of Study in the UK
7 years, 0 months, 1 days
Research summary
This study is an observational, prospective study enrolling patients diagnosed with the fusion gene defining the ultra-rare subtype of Sarcoma, Epithelioid Haemangioendothelioma. There is currently no standard of treatment that has proven to be consistently effective in this patient group. This study aims to identify clinical biomarkers to predict outcomes and improve the prognosis for these patients. Clinical data and blood/tissue samples will be collected prospectively in line with standard of care treatment and analysed for proteomic data at the Institute of Cancer Research, London. Samples and clinical data will also be collected in the same manner at the sponsor centre, Fondazione IRCCS Istituto Nazionale Tumori (Milan, Italy) and will additionally undergo hormone analysis. Recruitment at the Royal Marsden will span 3 years and aims to recruit approximately 18 patients over that period. Patients will be followed up for 3 years after the recruitment period has ceased.
REC name
North West - Greater Manchester West Research Ethics Committee
REC reference
21/NW/0187
Date of REC Opinion
29 Sep 2021
REC opinion
Further Information Favourable Opinion